Forte Biosciences, INC. (FBRX) — 10-Q Filings

10-Q Filings (6)

• Forte Biosciences' Losses Widen Amid R&D Surge, Cash Position Strengthens — Nov 14, 2025 Risk: high
  Forte Biosciences, Inc. (FBRX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $44.587 million, up from $28.3
• Forte Biosciences' Cash Soars Amid Rising R&D, Widening Losses — Aug 14, 2025 Risk: high
  Forte Biosciences, Inc. (FBRX) reported a net loss of $26.9 million for the six months ended June 30, 2025, an increase from a net loss of $19.9 million for the
• Forte Biosciences Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Forte Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Tocagen Inc., is involved in pharmaceutical preparat
• Forte Biosciences Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Forte Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of
• Forte Biosciences Q2 2024 Update — Aug 14, 2024 Risk: medium
  Forte Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the second quarter of 202
• Forte Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
  Forte Biosciences, Inc. (FBRX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Forte Biosciences, Inc. filed a 10-Q report for the period ending M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX